This article is issued on behalf of Treatment.com AI Inc. Centrally Positioned AI Co. Platform Designed To Transform Healthcare
Contributed Opinion 
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA).
Co. Prepares to Roll Out Wound Irrigating Solution
Research Report
Interim Data From TID Trial Are Positive
Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch
Biopharma Receives PDUFA Date for Lead Program
Research Report
New Cell Treatment for Bladder Cancer Shows Promise
Research Report
Biopharma Shares Efficacy Data at AUA Meeting
Research Report
Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock.Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.One Co. With Cell Holding Device Stands Out in T1D Space
Research Report
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. Biotech Company Reports Promising Neurological Treatment in Clinical Study
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year.Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.Biotech Discovers Revolutionary Immunotherapy in Houston
Research Report
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note. Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Research Report
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential. Four-Year Data on New Drug for Early AD Positive
Research Report
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Research Report
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. 
Streetwise Key Charts
